首頁 產業/市場分類 出版商一覽 Email 通知 GII媒體代理會議 公司簡介 聯絡我們
- English Japanese Korean
首頁 > 市場調查報告書 > 製藥 > 製藥企業 > Recordati:製藥企業分析報告
產業/市場分類
製藥 (4807)
肥胖症治療 (44)
非專利藥 (129)
疫苗 (181)
神經疾病 (172)
骨頭疾病治療 (37)
動物用醫藥 (17)
處方藥 (156)
規章 (126)
感染疾病 (346)
精神病 (84)
製藥企業 (524)
糖尿病 (191)
癌症 (903)
藥物開發 (1449)
DDS (182)
OTC 非處方藥 (150)
市場調查報告書

Recordati:製藥企業分析報告

Recordati: Pipeline * Products * Performance * Potential

出版商 Espicom Business Intelligence
出版日期 2009年09月 商品編碼 17860
內容資訊 英文 Pages: 78
價格
US $ 1040 Hard Copy
US $ 1040 PDF by E-mail (Single user license)
US $ 1040 Web Access (Single user license)


Recordati:製藥企業分析報告 是由出版商Espicom Business Intelligence在2009年09月所出版的。 這份英文市場調查報告書包含Pages: 78 價格從美金1040起跳。

目錄

Abstract

Pharmaceutical company intelligence reports from Espicom provide a full review of the company' s activities together with five-year sales forecasts for its key products. The company' s financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company' s product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events.

Table of Contents

EXECUTIVE SUMMARY

A detailed and comprehensive overview of current financial position, company strategy, product and pipeline analysis.

THERAPEUTIC AREA FOCUS

  • Key product analysis and forecasting
  • Cardiovascular
  • Zanidip/Zanedip (lercanidipine)
  • Central Nervous System
  • Elopram (citalopram)
  • Entact (escitalopram)
  • Tradorec XL (tramadol)
  • Gastroenterology/Urology
  • Peptazol/Ulcotenal (pantoprazole)
  • Respiratory
  • Exomuc and Hexa (acetylcysteine and biclotimol)
  • Anti-Infectives
  • Isocef (ceftibuten)

OPERATIONAL DATA

  • A wealth of background and detail
  • A full 5-year financial performance assessment
  • Key agreements
  • Infrastructure
  • Subsidiaries and joint ventures
Back to Top